Related Articles

• Explore Our Interactive Pipeline

  

  This interactive site provides an overview of clinical trials for assets within our GSK pipeline distributed across 4 pillars: immuno-oncology, oncology cell therapy, cancer epigenetics, and synthetic lethality.

  Read more »

• Our Pipeline Brochure

  

  GSK oncology is committed to the discovery and development of new oncology compounds that leverage patient-driven science to deliver improved outcomes for more patients.

  Read more »

• Belantamab Mafodotin-blmf Mechanism of Action

  

  Belantamab mafodotin-blmf (BLENREP) is only approved in the US for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome

  Read more »